Search for Abstracts Find by Title, Author or Description Year Abstracts - 2018 - 2017 - 2016 - 2015 - 2014 - 2013 - 2012 - 2011 - 2010 - 2009 Tags AB Applied Basic Science Basic Science BT Clinical OT Other P Poster T Search Reset Order by Title Alphabetical Title Reverse Alphabetical Most Recent First Oldest First Most popular first Last modified first AB01 – PRRT 2.0: Definition and Prediction of Efficacy with Circulating Neuroendocrine Tumor Transcripts Published in 2016 Listed under AB, Poster Download Bodei pdf Download Poster (872 KB) AB02 – Circulating Neuroendocrine Gene Transcripts – the NETest – Accurately Identify GEP-NETs, Are Decreased by Surgery and Predict Tumor Progression and Recurrence Published in 2016 Listed under AB, Poster Download Kidd pdf Download Poster (749 KB) AB03 – A Prognostic Model for Pulmonary Carcinoid Tumors Based on Large Chromosomal Alterations Published in 2016 Listed under AB Download Leventakos AB04 – Blood Gene Transcript Analysis Diagnoses Bronchopulmonary NETs and Identifies Progressive Disease Published in 2016 Listed under AB, Poster Download Lewczuk pdf Download Poster (924 KB) AB05 – Neuroendocrine Tumor Blood Transcript Analysis, the NETest, Predicts Gastroenteropancreatic Neuroendocrine Tumor Disease Status and is Prognostic for Progressive Disease Published in 2016 Listed under AB, Poster Download Pavel pdf Download Poster (932 KB) AB06 – Next-Generation Sequencing (NGS) in Pancreatic Neuroendocrine Tumors (panNETs): Defining Differentiation and Grade Genetically Published in 2016 Listed under AB, Poster Download Raj pdf Download Poster (481 KB) B01 – Genomic Profiling Distinguishes Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (GEP-NEC) from Small Cell Lung Carcinoma (SCLC) Published in 2016 Listed under Basic Science Download Bergsland B02 – Correlation of Angiogenic Markers in Neuroendocrine Tumors and Their Prognostic Implications Published in 2016 Listed under Basic Science, Poster Download Beyer pdf Download Poster (421 KB) B03 – Immune Checkpoint Markers and Immune Response in Well Differentiated Neuroendocrine Tumors (NET) of the Small Intestine and Pancreas Published in 2016 Listed under Basic Science Download da Silva B04 – Loss of UCHL1 Expression Increases Metastatic Potential in Pancreatic Neuroendocrine Tumors Published in 2016 Listed under Basic Science Download Finnerty B05 – Development of Non-Metastatic and Metastatic Xenograft Models of Pancreatic Neuroendocrine Disease for Defining the Molecular Landscape Responsible for Progression and Therapeutic Outcome Published in 2016 Listed under Basic Science Download Glenn B06 – Met Activation Confers Increased Aggressiveness and Corresponds with Hypoenhancement on Contrast Enhanced Computed Tomography in Pancreatic Neuroendocrine Tumors Published in 2016 Listed under Basic Science Download Krampitz B07 – New Image-guided Alpha Particle Therapy for NETs in Children and Adults Published in 2016 Listed under Basic Science Download Lee B08 – Novel Combinatorial Drug Therapy for MTC Published in 2016 Listed under Basic Science Download Pozo B09 – Enhancing Neuroendocrine (NET) Cancer Therapy Responses via Disruption of Peroxide Balance Published in 2016 Listed under Basic Science Download Rodman B10 – RABL6A, A Novel Oncogene Required for Akt-mTOR and Myc Signaling in Pancreatic Neuroendocrine Tumor Cells Published in 2016 Listed under Basic Science Download Sheehy B11 – The 2nd Gen mTOR inhibitor INK128 Overcomes Resistance to Everolimus (1st Gen) in Pancreatic Neuroendocrine Tumors Published in 2016 Listed under Basic Science Download Wang B12 – The Pentarin Miniaturized Drug Conjugate PEN-221 Targets the Potent Cytotoxic DM1 To Somatostatin 2 Receptor Expressing Cancers Published in 2016 Listed under Basic Science Download Whalen B13 – Distinctive Chromosomal Instability (CIN) Patterns and its Prognostic Value in Pancreatic Neuroendocrine Tumors (pNET) Published in 2016 Listed under Basic Science Download Yao B14 – TR4: A Potential Therapeutic Target in NETs Published in 2016 Listed under Basic Science Download Zhang B15 – CgA Depletion Inhibits Neuroendocrine Tumor Cell Growth and Alters Phenotype Published in 2016 Listed under Basic Science Download Zhang C01 – Simulated-Use Study of a Single-Use Delivery Device for Lanreotide Depot in Untrained Health Care Professionals Published in 2016 Listed under Clinical, Poster Download Adelman pdf Download Poster (5.41 MB) C02 – Impact of Prior Somatostatin Analogue (SSA) Use on Progression-free Survival (PFS) in Patients with Advanced Nonfunctional Neuroendocrine Tumors (NET) of Lung or Gastrointestinal (GI) Origin: A Secondary Analysis from the RADIANT-4 Study Published in 2016 Listed under Clinical Download Buzzoni C03 – Escalated Dose Somatostatin Analogues (SSA) in Management of NETs: A Systematic Review Published in 2016 Listed under Clinical Download Chan C04 – Efficacy and Safety of Everolimus in Advanced, Progressive ,Nonfunctional Neuroendocrine Tumors (NET) of the Lung: A Subgroup Analysis of the Phase 3 RADIANT-4 Study Published in 2016 Listed under Clinical, Poster Download Fazio pdf Download Poster (485 KB) C05 – Efficacy of Lanreotide Depot/Autogel for Symptomatic Control of Carcinoid Syndrome (CS) in Neuroendocrine Tumor Patients: Follow-up Analysis of the ELECT Prospective, Randomized, Doubleblind and Open-label Phases Published in 2016 Listed under Clinical, Poster Download Fisher, Jr pdf Download Poster (927 KB) C06 – Pharmacokinetic (PK) Differences Between Subcutaneous and Intramuscular Administration of Lanreotide: Results from a Phase I Study Published in 2016 Listed under Clinical, Poster Download Manon pdf Download Poster (2.26 MB) C07 – Capecitabine and Temozolomide (C/T) Combination Therapy in Patients (pts) with Advanced Neuroendocrine Neoplasms (aNEN) and the Role of O6-methylguanine-methyltransferase (MGMT) as a Potential Biomarker for Response Published in 2016 Listed under Clinical, Poster Download Owen pdf Download Poster (519 KB) C08 – Efficacy and Safety Results of Telotristat Ethyl in Patients with Carcinoid Syndrome During the Double-blind Treatment Period of the TELECAST Phase 3 Clinical Trial Published in 2016 Listed under Clinical Download Pavel C09 – Impact of Prior Chemotherapy (Chemo) on Progression-free Survival (PFS) in Patients (Pts) with Advanced, Nonfunctional Lung or Gastrointestinal (GI) Neuroendocrine Tumors (NET): A Secondary Analysis from The Phase 3 RADIANT-4 Study Published in 2016 Listed under Clinical Download Pommier C10 – The Efficacy and Safety of Sunitinib in Patients with Advanced Well-differentiated Pancreatic Neuroendocrine Tumors Published in 2016 Listed under Clinical Download Raymond C11 – Lanreotide Autogel/Depot (LAN) Post-Octreotide Long-Acting Release (OCT) for Safe and Tolerable Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Published in 2016 Listed under Clinical, Poster Download Saif pdf Download Poster (669 KB) C12 – Use of Alklyating Chemotherapy in High Grade Neuroendocrine Tumours: Evaluation of Real World Data Published in 2016 Listed under Clinical Download Sathiyapalan C13 – Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety from a RADIANT-4 Subgroup Analysis Published in 2016 Listed under Clinical Download Singh C14 – Phase I, Multi-center, Open-label, Dose-escalation Study of Pasireotide LAR (PAS) in Patients With Advanced Neuroendocrine Tumors (NET) Published in 2016 Listed under Clinical Download Strosberg C15 – Long-term Safety/Tolerability of Lanreotide Autogel/Depot (LAN) in Neuroendocrine Tumors (NETs) Patients with Carcinoid Syndrome (CS): The ELECT Long-term Open-label Extension Published in 2016 Listed under Clinical, Poster Download Vinik pdf Download Poster (828 KB) C16 – Everolimus (EVE) in Advanced, Nonfunctional, Well-differentiated Neuroendocrine Tumors (NET) of Gastrointestinal (GI) or Lung Origin: Second Interim Overall Survival (OS) Results From the RADIANT-4 Study Published in 2016 Listed under Clinical Download Yao C17 – Pitfalls in the Response Evaluation after Peptide Receptor Radionuclide Therapy with [177Lu-DOTA0,Tyr3]Octreotate Published in 2016 Listed under Clinical Download Brabander C18 – Long-term Efficacy, Survival and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors Published in 2016 Listed under Clinical Download Brabander C19 – Long-term Efficacy, Survival and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors Published in 2016 Listed under Clinical Download Brabander C20 – Tumor Growth Rate (TGR) in Intestinal/Pancreatic Neuroendocrine Tumors: Post hoc Exploratory Analysis of Data from the CLARINET Study Published in 2016 Listed under Clinical, Poster Download Caplin pdf Download Poster (824 KB) C21 – Evaluation of Uncinate Process Uptake on DOTA-TOC PET/MRI Published in 2016 Listed under Clinical Download Hope C22 – Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Neuroendocrine Tumors (NETs): A United States Experience Published in 2016 Listed under Clinical Download Katona C23 – Personalized Dosimetry Based Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors with 90Y-DOTATOC Published in 2016 Listed under Clinical Download Menda C24 – Magnetic Resonance Imaging of Neuroendocrine Tumor Hepatic Metastases: Evaluation of Lesion Conspicuity and Interobserver Agreement of Lesion Measurements on Various Sequences Published in 2016 Listed under Clinical, Poster Download Morse pdf Download Poster (319 KB) C25 – Improved Survival in Stage IV NETs Treated with High Dose I-131 MIBG is Predicted by Response at Initial Follow up and by Multiple Rounds of Therapy Published in 2016 Listed under Clinical Download Morse C26 – NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup Analysis Published in 2016 Listed under Clinical Download Strosberg C27 – Does Receptor Status Impact Survival of Patients with Neuroendocrine Tumors? Published in 2016 Listed under Clinical Download Wang C28 – Prospective Experience with Routine SSTR2A Immunohistochemistry in Neuroendocrine Epithelial Neoplasms Published in 2016 Listed under Clinical Download Alkapalan C29 – Identification of Recurrence Predictors in Stage I-III Midgut NETs After Curative Surgery Published in 2016 Listed under Clinical Download Cives C30 – Multiple and Secondary Hormone Secretion in Patients with Metastatic Pancreatic Neuroendocrine Tumors Published in 2016 Listed under Clinical Download Crona C31 – Identification of Primary Tumors in Patients Presenting with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Published in 2016 Listed under Clinical Download Keck C32 – Higher Tumor Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival Published in 2016 Listed under Clinical Download Keck C33 – Outcome of Surgical Resection after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT) for Pancreatic Neuroendocrine Neoplasms: A Case-matched Analysis Published in 2016 Listed under Clinical, Poster Download Partelli pdf Download Poster (1.16 MB) C34 – Number of Positive Nodes and Their Localization Correlate with Recurrence in Pancreatic Neuroendocrine Neoplasms: Implications for Surgery, Staging and Surveillance Published in 2016 Listed under Clinical, Poster Download Partelli pdf Download Poster (477 KB) C35 – Liver Needle Biopsies are Poor Predictors of Histologic Tumor Grade for Midgut Neuroendocrine Tumors Published in 2016 Listed under Clinical Download Ramirez C36 – Outcomes for Patients with Surgically Resected Thymic Neuroendocrine Tumors Published in 2016 Listed under Clinical Download Sceusi C37 – Neoplasia in Patients with Atrophic Metaplastic Autoimmune Gastritis (AMAG): Screening and Surveillance Endoscopy Should Become Standard of Care Published in 2016 Listed under Clinical Download Stashek O01 – Addressing Neuroendocrine Tumour Related Emotional Issues Published in 2016 Listed under Other Download Ardill O02 – Evidence of Improved Survival when Patients are Referred on to a Specialist NET Clinic with Multidisciplinary Team Management Published in 2016 Listed under Other Download Ardill O03 – What Matters Most? An Exploration of Decision Criteria Considered by Patients with GEP-NET and Physicians Using Holistic Multi-Criteria Decision Analysis Published in 2016 Listed under Other, Poster Download Goetghebeur pdf Download Poster (1.03 MB) O04 – To Treat or Watch? Identifying Drivers of Decisions for Patients with GEPNET Using Reflective Multi-Criteria Decision Analysis Published in 2016 Listed under Other Download Goetghebeur O05 – A Case Series of 27 Primary Ovarian Neuroendocrine Tumors Published in 2016 Listed under Other Download Heskel O06 – Retrospective Chart Review of Antidepressant Use in Patients with Carcinoid Tumors Published in 2016 Listed under Other, Poster Download Isenberg-Grzeda pdf Download Poster (254 KB) O07 – Antidepressant Use in Patients with Carcinoid Tumors: Results of A Systematic Review Published in 2016 Listed under Other, Poster Download Isenberg-Grzeda pdf Download Poster (383 KB) O08 – Renal Neuroendocrine Tumors (rNETs): A Single-center Experience Published in 2016 Listed under Other, Poster Download Scales pdf Download Poster (78 KB) O09 – Identifying and Prioritising Gaps in Neuroendocrine Tumour Researchresults of the Delphi Consensus Project of the Commonwealth Neuroendocrine Tumour Research Collaboration (CommNETS) Published in 2016 Listed under Other Download Segelov O10 – The Clinicopathologic Characteristics of Primary Presacral Neuroendocrine Tumor: A Single Center Experience Published in 2016 Listed under Other, Poster Download Yang pdf Download Poster (671 KB) P01 – Economic Burden of Illness of Malignant Gastrointestinal Neuroendocrine Tumors (NET) Published in 2016 Listed under P, Poster Download Cai pdf Download Poster (338 KB) P02 – Economic Burden of Illness of Malignant Lung Neuroendocrine Tumors (NET) Published in 2016 Listed under P, Poster Download Cai pdf Download Poster (352 KB) P03 – Epidemiology of Gastrointestinal Neuroendocrine Tumors (GI-NET) in the US: Analysis of 2 Large Insurance Claims Databases Published in 2016 Listed under P, Poster Download Cai pdf Download Poster (413 KB) P04 – Epidemiology of Neuroendocrine Tumors (NET) of the Lung in the US: Analysis of 2 Large Insurance Claims Databases Published in 2016 Listed under P, Poster Download Cai pdf Download Poster (462 KB) P05 – Neuroendocrine Tumor Incidence Over 18 years: Kentucky Cancer Registry vs SEER Published in 2016 Listed under P Download Chauhan P06 – The Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Pancreatic Neuroendocrine Tumors Confined to and Extending Beyond the Pancreas Published in 2016 Listed under P, Poster Download Conrad pdf Download Poster (709 KB) P07 – Comparative Study of Pulmonary and Extrapulmonary High Grade Neuroendocrine Carcinomas: A SEER Database Analysis of 210195 Cases Published in 2016 Listed under P Download Dasari P08 – Survival Trends of Neuroendocrine Tumors and Associated Prognostic Factors Published in 2016 Listed under P Download Dasari P09 – Understanding a Rare Disease’s Impact on Health Systems: A Population-Based Analysis of Patterns and Drivers of Costs for Neuroendocrine Tumors Costs Published in 2016 Listed under P Download Hallet P10 – Access to Care and Outcomes for Neuroendocrine Tumors: Does Socio-Economic Status Matter? A Population-based Analysis Published in 2016 Listed under P Download Hallet P11 – Health-related Quality of Life (HRQoL) in Patients with Advanced, Nonfunctional, Well-differentiated Gastrointestinal (GI) or Lung Neuroendocrine Tumors (NET) in the Phase 3 RADIANT-4 Trial Published in 2016 Listed under P Download Pavel P12 – Health-related Quality of Life (HRQoL) in Patients with Advanced Neuroendocrine Tumors (NET) by Tumor Origin in the Phase 3 RADIANT-4 Trial Published in 2016 Listed under P Download Pavel P13 – Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors (mGEP-NETs) Published in 2016 Listed under P Download Pulgar P14 – Incidence and Prevalence of Neuroendocrine Tumors in the United States 1973-2012 Published in 2016 Listed under P Download Shen P15 – Functional Status and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients Published in 2016 Listed under P Download Shen P16 – Association of Disease Progression, Health-related Quality of Life (HRQoL), and Utility in Patients with Advanced, Nonfunctional, Welldifferentiated Gastrointestinal (GI) or Lung Neuroendocrine Tumors (NET) in the Phase 3 RADIANT-4 Trial Published in 2016 Listed under P Download Singh T01 – Cisplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery Published in 2016 Listed under T Download Eads T02 – A Phase II Trial of LEE011 in Combination with Everolimus in the Treatment of Advanced Well Differentiated Neuroendocrine Tumors of Foregut Origin Published in 2016 Listed under T Download Raj T03 – SPINET: A Randomized, Double-blind, Placebo-controlled Phase III Study of Lanreotide Autogel/Depot (LAN) in Patients with Advanced Lung Neuroendocrine Tumors Published in 2016 Listed under Poster, T Download Reidy-Lagunes pdf Download Poster (804 KB) 5 10 15 20 25 30 50 100